Inducible nitric oxide synthase contributes to gender differences in ischemic brain injury.
Estrogens have antiinflammatory actions and protect the brain from ischemic injury. Cerebral ischemia is accompanied by an inflammatory reaction that contributes to the tissue damage, an effect mediated in part by toxic amounts of nitric oxide (NO) produced by the inducible isoform of NO synthase (iNOS). Therefore, estrogens may protect the female brain by modulating postischemic iNOS expression. To test this hypothesis, we studied whether iNOS plays a role in the mechanisms of the reduced susceptibility to ischemic injury observed in female mice. The middle cerebral artery was occluded for 20 mins using an intraluminal filament in C57Bl/6 mice, and infarct volume was assessed 3 days later in cresyl violet-stained sections. Infarcts were 53% smaller in female mice than in males (P < 0.05), a reduction abolished by ovariectomy (OVX) and reinstated by estrogen replacement. In normal female mice, postischemic iNOS mRNA was lower than in males (P < 0.05). Ovariectomy increased iNOS mRNA after ischemia and estrogen replacement blocked this effect. Furthermore, the iNOS inhibitor aminoguanidine reduced infarct volume in male, but not in female, mice. Similarly, male iNOS-null mice had smaller infarcts than wild-type mice, but female iNOS nulls were not protected. Ovariectomy and OVX with estrogen replacement did not affect infarct volume in iNOS-null female mice. The findings suggest that the neuroprotection conferred by estrogens is, in part, related to attenuation of iNOS expression. Such attenuation could result from the potent antiinflammatory effects of estrogens that downregulate iNOS expression via transcriptional or posttranscriptional mechanisms.
Park
Eun-Mi
EM
Division of Neurobiology, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, 10021, USA.
Cho
Sunghee
S
Frys
Kelly A
KA
Glickstein
Sara B
SB
Zhou
Ping
P
Anrather
Josef
J
Ross
Margaret E
ME
Iadecola
Costantino
C
D000818:Animals; D002544:Cerebral Infarction / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000235:genetics; D006146:Guanidines / Q000494:pharmacology; D002546:Ischemic Attack, Transient / Q000150:complications / Q000201:enzymology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D010052:Ovariectomy; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000235:genetics; D012737:Sex Factors
D004791:Enzyme Inhibitors; D006146:Guanidines; D012333:RNA, Messenger; D052247:Nitric Oxide Synthase Type II; C004479:pimagedine